



MSD

AstraZeneca



CECOG

Central European Cooperative Oncology Group

A Guide To Genetic Consenting

Module 4: What is mainstream consenting?

Prof. Christian Singer

The information contained within these educational materials is not intended to be professional advice and is not intended to replace personal consultation with a doctor, pharmacist, or other health care professional. The reader should not disregard medical advice or delay seeking it because of something found on this site. This information has been organised and fully funded by AstraZeneca and MSD in collaboration with the Central European Cooperative Oncology Group (CECOG). The views expressed in this publication reflect the experience and opinions of the authors and not necessarily that of MSD / AstraZeneca / CECOG.

Z4-45911

Date of preparation: June 2022

Learning objectives

The primary purpose of this learning module is to inform and educate non-genetics HCPs on genetic consenting.

This module will enable HCPs to:

- Understand the traditional approach to genetic consenting as well as its' challenges
- Be aware of alternative models of genetic consenting
- Define mainstream genetic testing for pathogenic gene variants for patients with cancer



What is mainstream genetic consenting vs. traditional genetic consenting?

Traditional

It is practiced in person with patients travelling to a healthcare facility to meet with a genetics clinician or counsellor^{1,2}

Mainstream

This is performed through a non-genetics team, such as oncologists, surgeons and clinical nurse specialists as part of their existing appointments, with support as required from a genetics service¹



Advantages of mainstream consenting vs. traditional genetic consenting



Improvement in turnaround times for genetic test results



Facilitates increased access to genetic tests



Creates closer collaboration between geneticists and non-genetics HCPs



Who can perform mainstream genetic consenting?

- Mainstream genetic consenting may be delivered by any member of the oncology team who has received appropriate training to do so, including oncologists, surgeons and clinical nurse specialists, working together as part of the multidisciplinary team



- Use of digital content may be considered



Summary

- Mainstream consenting is performed through a non-genetics team, such as oncologists, surgeons and clinical nurse specialists as part of their existing appointments, with support as required from a genetics service¹
- Advantages of mainstream consenting vs. traditional genetic consenting include improvements in turnaround times for genetic test results, increased access to genetic tests as well as closer collaboration between geneticists and non-genetics HCPs²

HCP=healthcare professional

1. Rahman N. *Clin Med.* 2014; 14:436-439; 2. Bokkers K, et al. *Cancers.* 2022;14:1059.

